Lupus Science & Medicine

Papers
(The H4-Index of Lupus Science & Medicine is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Evaluation and randomised controlled trial of home urinalysis testing in patients with SLE at elevated risk for developing lupus nephritis: a study protocol51
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort47
Combining mepacrine with hydroxychloroquine-based therapy in active systemic lupus erythematosus: an observational study of 106 patients from the Lupus-Cruces cohort43
Towards a minimal core dataset for systemic lupus erythematosus studies38
B lymphocytes in treatment-naive paediatric patients with lupus are epigenetically distinct from healthy children36
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus35
High-dimensional analysis of T-cell profiling variations following belimumab treatment in systemic lupus erythematosus32
Differences in reproductive health discussions in an urban Hispanic population with SLE: lessons from the field28
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE28
Validation of proposals for definitions of moderate and severe disease activity in SLE: impact on flares, quality of life, damage accrual, hospitalisations and mortality25
Genetic load in incomplete lupus erythematosus25
Novel multiclass classification machine learning approach for the early-stage classification of systemic autoimmune rheumatic diseases23
Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease23
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms22
Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus22
Add-on sirolimus for the treatment of mild or moderate systemic lupus erythematosus via T lymphocyte subsets balance22
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials22
Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial21
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit21
A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort20
VPS13C and STING expression in neuropsychiatric systemic lupus erythematosus: unveiling an unbreached territory20
0.092554092407227